Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

BACKGROUND: Lipotoxicity leading to excessive caspase‐mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan‐caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. AIMS: To assess whether 28 da...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Randomised Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587784/
https://www.ncbi.nlm.nih.gov/pubmed/30430605
http://dx.doi.org/10.1111/apt.15030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587784/
https://www.ncbi.nlm.nih.gov/pubmed/30430605
http://dx.doi.org/10.1111/apt.15030

Ejemplares similares